Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Books
  • Technology
  • Manufacturing
  • Health
  • Financial
  • Artificial Intelligence
ncarol.com

Lineus Medical Announces a Reduction in Price for SafeBreak Vascular
ncarol.com/10271492

Trending...
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
  • Santa Your Way Announces Official 2026 Q4 Holiday Tour: Booking Open For Santa, The 5-star Grinch, And Dual Character Experiences Nationwide
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
SafeBreak Vascular Lineus Medical
FAYETTEVILLE, Ark. - ncarol.com -- Lineus Medical announces a significant reduction in price of nearly 15% for its flagship product, SafeBreak Vascular, in the United States. After creating a new device classification with the FDA and becoming the first break-away device available for IV lines in the US, SafeBreak Vascular was first released with a list price of $6.90. Since its release, increased sales volume and concentrated efforts toward manufacturing efficiencies support a price adjustment with a new list price of $5.90, effective on September 1st, 2024.

SafeBreak Vascular is the only break-away device for IV lines proven to reduce IV complications1.  When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.

More on ncarol.com
  • Port St. Lucie REALTOR® Irene Pernice Earns SFR® Certification
  • AMR and UAS Take the Stage at WorldSkills Shanghai 2026
  • KayeDinero Named a Song After RetroArch. Gamers Already Know Why
  • Drake Says He'll Tour in 2027. KayeDinero Has One Question: Asheville?
  • Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand

"A large focus of our strategy is maximizing our economic value proposition for the hospital." Lineus Medical's Vice President of Sales, Larry Hayes comments, "Reducing our price allows for both current and new accounts to take advantage of cost savings, and in doing so, we are making it easier for hospitals to invest in improved vascular access care for their patients."

Vance Clement, CEO of Lineus Medical, stated, "Inflation is hitting everyone, and we are all used to prices going up.  This is especially true in healthcare, where prices never go down. However, SafeBreak, which is proudly made in the USA, is changing that. As we continue to grow, we will keep investing in manufacturing so that we can lower the cost of SafeBreak again in the future."

Lineus Medical is committed to improving patient safety and advancing vascular access care and believes that this price reduction is another important step in our mission to remove the pains associated with medical lines.  Anyone interested in SafeBreak Vascular's price reduction can visit our website www.lineusmed.com to learn more.

About Lineus Medical

Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications1. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn.

Contact
Vance Clement
***@lineusmed.com


Source: Lineus Medical
Filed Under: Health, Technology

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Acuvance Coker Study Finds Experience, Not Supply, Is the Biggest Advanced Practice Provider Workforce Challenge
  • Uk Financial Moonshot Token™ Robinhood-chain Goes Live On Tokpie Exchange Tomorrow, With Solana Side Of UKFLMS To Follow In Global Listing Expansion
  • KayeDinero Took Her Voice Off the Beat — And Says the Music Got More Personal
  • Solid Earth's new "Welcome to Real Estate" campaign introduces RealtyID™: Know Before Your Open the Door
  • KayeDinero Didn't Stop Writing. She Stopped Putting Words on the Beat
  • Radio Drive's New Album Walk With Me Delivers Two GRAMMY® Submissions Across Rock and Alternative Categories
  • Before Python, There Was Chess: KayeDinero Makes Her Next Move With "Checkmate"
  • Kaplan Morrell and Attorney Jacqui Condon Selected to Represent Professional Women's Soccer Players in Workers' Compensation Matters
  • ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
  • Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
  • Revenue Optics Names Prat Patibandla Director of Growth Marketing
  • VMACS Offers Battery-Powered Heat & AC Systems for RVs and Vans
  • Independent Autopsies Are Changing Civil Cases: Kansas City Forensic Explains Why Families Are Seeking Second Opinions
  • JEGS Launches Transformed Digital Commerce Platform Powered by PhaseZero
  • Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville
  • Cummings Graduate Institute Celebrates New Doctor of Behavioral Health Graduates
  • Data Tiles Challenges the Data Product Status Quo Following Antwerp Summit
  • Visit London Appoints The SEO Works for AI-First Search Strategy
  • Inglewood Associates and Gordon Brothers Provide Update on Sale Process for 925 Euclid Avenue in Cleveland
  • Century Fasteners Corp. Exhibiting at the 2026 International Fastener Expo
_catLbl0 _catLbl1

Popular on ncarol.com

  • Parksy (parksy.com) Tackles the Most Common Parking Problem Nobody Talks About: Finding the Car Again - 172
  • Mito Health Passes One Million Lab Tests, Expands to Seven Categories of Preventive Health Testing - 171
  • Free JavaScript Charting Library ProEssentialsJS Permits Commercial Use. Highcharts, SciChart and LightningChart Free Tiers Do Not - 153
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A! - 137
  • Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History - 136
  • From Temecula Wine Country to Canyon Lake: Parkway Construction Transforms Outdoor Spaces for Inland Homeowners - 131
  • Bspin Launches Lightning-Fast Crypto Gaming Expansion With Sportsbook, Poker, VIP Rewards, and Bitcoin Lightning Network Integration - 130
  • Patented Foodservice Products Company with Strong Gross Margins and Substantial Two-Year Revenue Growth Hits Market for $1.6 Million - 126
  • Gigasoft 2026 JavaScript Chart Comparison: ProEssentials, Highcharts, SciChart, LightningChart, ECharts - 123
  • Steve Thompson Launches StickyHealth to Tackle the Retention Gap in the Growing GLP 1 Market - 119

Similar on ncarol.com

  • Woodside Rehab & Nursing Enters a New Era of Clinical Excellence and Growth
  • Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
  • Nurses Honored at NCNA Annual Convention
  • AMR and UAS Take the Stage at WorldSkills Shanghai 2026
  • Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand
  • Shanghai Chengwei Semiconductor Equipment Launches High Precision Laboratory Central Gas Supply System
  • Acuvance Coker Study Finds Experience, Not Supply, Is the Biggest Advanced Practice Provider Workforce Challenge
  • Uk Financial Moonshot Token™ Robinhood-chain Goes Live On Tokpie Exchange Tomorrow, With Solana Side Of UKFLMS To Follow In Global Listing Expansion
  • ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
  • Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute